- Home
- BHE vs SNDX Comparison
BHE vs SNDX Comparison
Compare BHE & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHE
- SNDX
- Stock Information
- Founded
- BHE 1979
- SNDX 2005
- Country
- BHE United States
- SNDX United States
- Employees
- BHE N/A
- SNDX N/A
- Industry
- BHE Electrical Products
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- BHE Technology
- SNDX Health Care
- Exchange
- BHE Nasdaq
- SNDX Nasdaq
- Market Cap
- BHE 1.3B
- SNDX 1.1B
- IPO Year
- BHE 1990
- SNDX 2016
- Fundamental
- Price
- BHE $39.26
- SNDX $9.99
- Analyst Decision
- BHE Strong Buy
- SNDX Strong Buy
- Analyst Count
- BHE 2
- SNDX 11
- Target Price
- BHE $47.00
- SNDX $34.00
- AVG Volume (30 Days)
- BHE 186.2K
- SNDX 1.7M
- Earning Date
- BHE 07-30-2025
- SNDX 08-04-2025
- Dividend Yield
- BHE 1.75%
- SNDX N/A
- EPS Growth
- BHE N/A
- SNDX N/A
- EPS
- BHE 1.44
- SNDX N/A
- Revenue
- BHE $2,612,294,000.00
- SNDX $43,722,000.00
- Revenue This Year
- BHE $0.52
- SNDX $431.08
- Revenue Next Year
- BHE $8.50
- SNDX $105.38
- P/E Ratio
- BHE $27.01
- SNDX N/A
- Revenue Growth
- BHE N/A
- SNDX N/A
- 52 Week Low
- BHE $30.73
- SNDX $8.58
- 52 Week High
- BHE $52.57
- SNDX $23.37
- Technical
- Relative Strength Index (RSI)
- BHE 50.47
- SNDX 52.52
- Support Level
- BHE $38.47
- SNDX $9.42
- Resistance Level
- BHE $40.51
- SNDX $10.54
- Average True Range (ATR)
- BHE 0.96
- SNDX 0.57
- MACD
- BHE -0.11
- SNDX 0.10
- Stochastic Oscillator
- BHE 37.11
- SNDX 56.80
About BHE Benchmark Electronics Inc.
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia and Europe of which key revenue is derived from the Americas.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.